India · Delayed Price · Currency is INR Emcure Pharmaceuticals Statistics
Total Valuation
NSE:EMCURE has a market cap or net worth of INR 353.21 billion. The enterprise value is 367.21 billion.
| Market Cap | 353.21B |
| Enterprise Value | 367.21B |
Important Dates
The last earnings date was Thursday, August 6, 2026.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | Sep 4, 2026 |
Share Statistics
NSE:EMCURE has 189.59 million shares outstanding. The number of shares has increased by 0.24% in one year.
| Current Share Class | 189.59M |
| Shares Outstanding | 189.59M |
| Shares Change (YoY) | +0.24% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 70.40% |
| Owned by Institutions (%) | 11.65% |
| Float | 41.62M |
Valuation Ratios
The trailing PE ratio is 34.92 and the forward PE ratio is 27.89. NSE:EMCURE's PEG ratio is 1.36.
| PE Ratio | 34.92 |
| Forward PE | 27.89 |
| PS Ratio | 3.65 |
| PB Ratio | 7.10 |
| P/TBV Ratio | 9.18 |
| P/FCF Ratio | 60.59 |
| P/OCF Ratio | 37.43 |
| PEG Ratio | 1.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.28, with an EV/FCF ratio of 62.99.
| EV / Earnings | 36.31 |
| EV / Sales | 3.79 |
| EV / EBITDA | 19.28 |
| EV / EBIT | 25.02 |
| EV / FCF | 62.99 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 2.61 |
| Interest Coverage | 9.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 16.94% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 4.08% |
| Revenue Per Employee | 14.39M |
| Profits Per Employee | 1.50M |
| Employee Count | 6,731 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:EMCURE has paid 3.71 billion in taxes.
| Income Tax | 3.71B |
| Effective Tax Rate | 26.69% |
Stock Price Statistics
The stock price has increased by +23.83% in the last 52 weeks. The beta is -0.06, so NSE:EMCURE's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | +23.83% |
| 50-Day Moving Average | 1,864.62 |
| 200-Day Moving Average | 1,606.99 |
| Relative Strength Index (RSI) | 43.01 |
| Average Volume (20 Days) | 161,655 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:EMCURE had revenue of INR 96.83 billion and earned 10.11 billion in profits. Earnings per share was 53.35.
| Revenue | 96.83B |
| Gross Profit | 57.55B |
| Operating Income | 14.68B |
| Pretax Income | 13.90B |
| Net Income | 10.11B |
| EBITDA | 19.05B |
| EBIT | 14.68B |
| Earnings Per Share (EPS) | 53.35 |
Balance Sheet
The company has 1.48 billion in cash and 15.21 billion in debt, with a net cash position of -13.74 billion or -72.46 per share.
| Cash & Cash Equivalents | 1.48B |
| Total Debt | 15.21B |
| Net Cash | -13.74B |
| Net Cash Per Share | -72.46 |
| Equity (Book Value) | 49.77B |
| Book Value Per Share | 261.12 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 9.44 billion and capital expenditures -3.61 billion, giving a free cash flow of 5.83 billion.
| Operating Cash Flow | 9.44B |
| Capital Expenditures | -3.61B |
| Depreciation & Amortization | 4.37B |
| Net Borrowing | 4.88B |
| Free Cash Flow | 5.83B |
| FCF Per Share | 30.75 |
Margins
Gross margin is 59.43%, with operating and profit margins of 15.16% and 10.44%.
| Gross Margin | 59.43% |
| Operating Margin | 15.16% |
| Pretax Margin | 14.35% |
| Profit Margin | 10.44% |
| EBITDA Margin | 19.67% |
| EBIT Margin | 15.16% |
| FCF Margin | 6.33% |
Dividends & Yields
This stock pays an annual dividend of 3.60, which amounts to a dividend yield of 0.19%.
| Dividend Per Share | 3.60 |
| Dividend Yield | 0.19% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.24% |
| Shareholder Yield | -0.05% |
| Earnings Yield | 2.86% |
| FCF Yield | 1.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:EMCURE is 2,214.29, which is 18.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 2,214.29 |
| Price Target Difference | 18.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 13.34% |
| EPS Growth Forecast (3Y) | 21.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |